Survey on the use of REKOVELLE for ovarian stimulation in assisted reproduction
REKOVELLE® PEN S.C. Injection 12μg/36μg/72μg for Controlled Ovarian Stimulation in Assisted Reproductive Technologies - General Drug Use-results Survey
This study is looking to see how well REKOVELLE works for helping women produce eggs during fertility treatments like IVF and ICSI by collecting their experiences and results.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Sex | Female |
| Sponsor | Ferring Pharmaceuticals Industry-sponsored |
| Locations | 1 site (Omitama, Ibaraki) |
| Trial ID | NCT06545877 on ClinicalTrials.gov |
What this trial studies
This observational survey focuses on the use of REKOVELLE for controlled ovarian stimulation in women undergoing assisted reproductive technologies, such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI). Participants who have received REKOVELLE will provide data on their experiences and outcomes, contributing to a better understanding of its effectiveness in developing multiple oocytes. The study aims to gather real-world evidence on the drug's use in daily practice without any exclusion criteria, allowing for a comprehensive assessment of its impact.
Who should consider this trial
Good fit: Ideal candidates for this survey are women who have received REKOVELLE during controlled ovarian stimulation for assisted reproductive technologies.
Not a fit: Patients who have not used REKOVELLE or are not undergoing assisted reproductive technologies may not benefit from this survey.
Why it matters
Potential benefit: If successful, this survey could enhance the understanding of REKOVELLE's effectiveness, potentially improving treatment protocols for infertility.
How similar studies have performed: While this survey is observational and focuses on real-world data, similar studies on ovarian stimulation have shown promising results in understanding treatment effectiveness.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants who received the REKOVELLE in controlled ovarian stimulation in assisted reproductive technologies and have consented to participate in the survey. Exclusion Criteria: * No exclusion criteria because data are collected under conditions of use in daily practice.
Where this trial is running
Omitama, Ibaraki
- Ferring Investigational Site — Omitama, Ibaraki, Japan (Recruiting)
Study contacts
- Study coordinator: Global Clinical Compliance
- Email: DK0-Disclosure@ferring.com
- Phone: +1 833-548-1402 (US/Canada)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.